Fox Run Management, L.L.C. Prothena Corp Public LTD CO Transaction History

Fox Run Management, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$19.54 - $26.15 $363,268 - $486,154	18,591 New	18,591 $383,000
Q4 2023 Feb 13, 2024	SELL	$32.31 - $52.32 $103,844 - $168,156	-3,214 Reduced 33.42%	6,403 $232,000
Q3 2023 Nov 07, 2023	BUY	$47.3 - $70.6 $454,884 - $678,960	9,617 New	9,617 $464,000
Q3 2022 Nov 07, 2022	SELL	$25.16 - $60.63 $145,726 - $351,168	-5,792 Reduced 44.84%	7,126 $432,000
Q2 2022 Aug 12, 2022	BUY	$22.73 - $39.98 $293,626 - $516,461	12,918 New	12,918 $351,000
Q3 2018 Oct 05, 2018	SELL	$12.7 - $15.79 $331,635 - $412,324	-26,113 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$10.99 - $44.21 $286,981 - $1.15 Million	26,113 New	26,113 $381,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.